| Jennifer L Osstifin-czerniejewski, PAC | |
|
23255 Eureka Rd, Taylor, MI 48180-5240 | |
| (734) 287-3000 | |
| (734) 287-3113 |
| Full Name | Jennifer L Osstifin-czerniejewski |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Location | 23255 Eureka Rd, Taylor, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821078411 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 5601003764 (Michigan) | Secondary |
| 363A00000X | Physician Assistant | 5601003764 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer L Osstifin-czerniejewski, PAC 23255 Eureka Rd, Taylor, MI 48180-5240 Ph: (734) 287-3000 | Jennifer L Osstifin-czerniejewski, PAC 23255 Eureka Rd, Taylor, MI 48180-5240 Ph: (734) 287-3000 |
News Archive
Are we ready for a future where brain scans invade our private thoughts? Will we have to alter our brains chemically to keep competitive at our jobs? Could science determine that "souls" do not exist, and, if so, what does that mean for how we think of ourselves as human beings?
Hundreds of cyclists, from experienced to novice, are signing up for Memory Ride to raise money and awareness to fight Alzheimer's disease. Set for Saturday, July 24, Memory Ride offers a challenging 100-mile "century" ride, as well as a "metric century" of 62 miles and a 20-mile option.
Web- and telehealth-based delivery of cognitive behavioral therapy is effective for treating chronic insomnia, giving rural-dwelling adults more choice and better access to services, researchers report.
New research has generated an unprecedented breakthrough for people with spinal cord injury. CEO Duncan Wallace said that work carried out by US scientists published this week shows that recovery after spinal cord injury may be possible in ways that were previously unimaginable.
Merck & Co., Inc., which operates outside the U.S. and Canada as MSD, today announced the European Commission (EC) approval of ELONVA® (corifollitropin alfa injection). ELONVA is indicated for controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART) program.
› Verified 9 days ago